Compounds > bromocriptine
Page last updated: 2024-08-23

bromocriptine and nafadotride

bromocriptine has been researched along with nafadotride in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azaryan, AV; Clock, BJ; Cox, BM1
Canales, JJ; Iversen, SD1
Floresco, SB; St Onge, JR1

Other Studies

3 other study(ies) available for bromocriptine and nafadotride

ArticleYear
Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation.
    Neurochemical research, 1996, Volume: 21, Issue:11

    Topics: Animals; Benzazepines; Bromocriptine; Cocaine; Dopamine Antagonists; Male; Naphthalenes; Nucleus Accumbens; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Opioid, mu; RNA, Messenger; Salicylamides; Transcription, Genetic; Up-Regulation

1996
Psychomotor-activating effects mediated by dopamine D(2) and D(3) receptors in the nucleus accumbens.
    Pharmacology, biochemistry, and behavior, 2000, Volume: 67, Issue:1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzopyrans; Bromocriptine; Grooming; Indoles; Motor Activity; Naphthalenes; Nucleus Accumbens; Oxazines; Piperidines; Pyrrolidines; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3

2000
Dopaminergic modulation of risk-based decision making.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:3

    Topics: Animals; Behavior, Animal; Benzamides; Benzazepines; Benzopyrans; Bromocriptine; Conditioning, Operant; Decision Making; Dextroamphetamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Naphthalenes; Oxazines; Piperazines; Pyridines; Pyrroles; Pyrrolidines; Rats; Rats, Long-Evans; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Reinforcement Schedule; Risk; Salicylamides

2009